Skip to main content

Advertisement

Table 2 Comparison of different interventional therapy (n = 10, each group)

From: Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia

Variables Sham Control Atorvastatin Rosiglitazone Combined
TG (mmol/L)      
TC (mmol/L) 3.31 ± 0.40* 4.99 ± 0.57 4.35 ± 0.65 4.92 ± 0.66 4.33 ± 0.64
LDL-C (mmol/L) 1.92 ± 0.38* 3.04 ± 0.44 2.77 ± 0.49 3.01 ± 0.71 2.88 ± 0.56
HDL-C (mmol/L) 0.89 ± 0.17 0.89 ± 0.12 0.89 ± 0.08 0.88 ± 0.25 0.86 ± 0.27
FBG (mmol/L) 4.44 ± 0.27 4.52 ± 0.43 4.62 ± 0.30 4.57 ± 0.50 4.49 ± 0.36
NO (umol/L) 10.61 ± 1.23* 6.04 ± 1.02# 7.53 ± 1.11 7.86 ± 1.07 8.41 ± 1.30&
MDA (nmol/mL) 0.95 ± 0.04* 3.97 ± 0.55# 3.26 ± 0.23 3.38 ± 0.27 2.52 ± 0.04&
CRP (mg/L) 1.97 ± 0.17* 4.64 ± 0.75# 3.96 ± 0.37 4.07 ± 0.28 3.26 ± 0.67&
ADMA (nmol/L) 47.38 ± 5.02* 67.15 ± 7.34# 58.09 ± 6.92 59.48 ± 6.11 53.34 ± 5.58&
15-d-PGJ 2 (pg/mL) 18.45 ± 1.23 21.66 ± 3.45# 30.40 ± 5.08 32.23 ± 5.53 37.26 ± 6.16&
  1. Denote: *p <0.05 versus other groups; #p <0.05 versus atorvastatin, rosiglitazone and combined groups; &p <0.05 versus atorvastatin and rosiglitazone groups.